𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Plasma sex hormone binding globulin in patients with prostatic carcinoma

✍ Scribed by Marco Grasso; Arturo Buonaguidi; Roberto Mondina; Giovanni Borsellino; Caterina Lania; Giuseppe Banfi; Patrizio Rigatti

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
459 KB
Volume
66
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Serum testosterone and sex hormone-bindi
Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma : A longitudinal study
✍ Ritva HeikkilΓ€; Kimmo Aho; Markku HeliΓΆvaara; Matti Hakama; Jukka Marniemi; Antt πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 60 KB πŸ‘ 1 views

## BACKGROUND. It has been hypothesized that high androgen levels are determinants of prostate carcinoma. ## METHODS. Serum concentrations of testosterone, sex hormone-binding globulin (SHBG), and androstenedione were analyzed to determine their role as predictors of prostate carcinoma in a lon

Suramin in combination with weekly epiru
Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma
✍ Alfredo Falcone; Andrea Antonuzzo; Romano Danesi; Giacomo Allegrini; Lencioni Mo πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 1 views

## BACKGROUND. Suramin and epirubicin are both active agents in the treatment of patients with hormone-refractory advanced prostate carcinoma, with demonstrated antitumor synergism in vitro on human prostate carcinoma cells and different dose-limiting toxicities. The authors conducted this Phase I

Oral estramustine and cyclophosphamide i
Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study
✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi